Navigation Links
FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder
Date:10/24/2011

SILVER SPRING, Md., Oct. 24, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the first generic versions of Zyprexa (olanzapine tablets) and Zyprexa Zydus (olanzapine orally disintegrating tablets) to treat schizophrenia and bipolar disorder.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Schizophrenia is a chronic, severe, and disabling brain disorder. About 1 percent of Americans have this illness. Symptoms people with schizophrenia have include: hearing voices, believing other people are reading their minds or controlling thoughts, and being suspicious or withdrawn.

Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. The symptoms of bipolar disorder include alternating periods of depression and high or irritable mood, increased activity and restlessness, racing thoughts, talking fast, impulsive behavior, and a decreased need for sleep.

"The approval of generic olanzapine offers greater access to a widely used treatment for mental illnesses," said Keith Webber, Ph.D., deputy director of the Office of Pharmaceutical Science in the FDA's Center for Drug Evaluation and Research. "Having affordable treatment options is good for patients with long-term illnesses that must be carefully managed."

Olanzapine must be dispensed with a Medication Guide that describes the risks and adverse reactions people should be mindful of when using the product. Olanzapine has a boxed warning alerting that this type of drug can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). Olanzapine is not approved for treating psychosis in the elderly with dementia.

Other serious risks of olanzapine include, high blood sugar (hype
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Onfi To Treat Severe Type of Seizures
2. FDA Approves Longer Duration Efficacy and Safety for EUFLEXXA®
3. FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
4. FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
5. FDA Approves Combination Therapy Juvisync
6. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
7. FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years
8. FDA Approves Soliris for Rare Pediatric Blood Disorder
9. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
10. FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer
11. FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... - Partnership aims to provide convenient access to vaccination ... at work, - "Let,s Fight Flu Together!" initiative ... to 18 years old(1), - Campaign goal is ... for those vaccinated, CAMBRIDGE, Mass., Nov. 10 ...
... Well-Tolerated, Significantly Inhibited ... November 10 at 8:30 ... a.m. ET-, NEW ... a biotechnology company focused on,the development of compounds for the treatment of cardiovascular ...
Cached Medicine Technology:Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 2Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 3Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 4Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 5Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 2VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 4VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 5VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 7VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 8
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences ... sell Arterosil and Arterosil HP, and that all claims and counterclaims have been ... Sciences, LLC (VHS) in the United States District Court for the Southern District ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The Kentucky ... workers are qualified for the position they are applying for, they are unable to ... many employers are considering altering drug testing policies in order to be able to ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
(Date:8/28/2015)... ... , ... “ Frequentz ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... to track product movement from beginning to end. , Businesses benefit greatly from having ...
(Date:8/28/2015)... Jordan, Utah (PRWEB) , ... August 28, 2015 ... ... been awarded a three-year accreditation for its adolescent residential, counseling, day treatment and ... demonstrates that it meets international standards for quality and its pursuit of excellence. ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... MedQuist Inc.,(Pink Sheets: MEDQ) announces that it ... Chain Systems, one of the nation,s largest ... and,allowing them to complete the MedQuist suite ... solutions. As partners, MedAssets and MedQuist ...
... 2 Filtrona Fibertec, a division of,Filtrona plc, ... fluid handling components, celebrated the completion,of the recent ... a Grand Opening,celebration. (Logo: http://www.newscom.com/cgi-bin/prnh/20061127/DCM011LOGO ... more than double the size of,production floor space ...
... Oct. 2 Abbott (NYSE: ABT ),announced today ... waived status under the Clinical Laboratory Improvement Amendements,of 1988 ... it,more widely available for use beyond the hospital setting. ... and accurate and,can be made more broadly available to ...
... California, October 2 joimax GmbH, Campbell,CA, is pleased ... Inc. the company is moving to larger premises in ... October 1st, 2007,joimax, Inc. will be located at ... CA 95008 USA "This move reflects the strong ...
... Genetic Engineering and,Biotechnology News, (GEN) first online video ... up by more than 180 media outlets since its,release ... to run on GEN,s,Biotech Video Channel, is a corporate ... the Multimedia News Release, go to:, http://www.prnewswire.com/mnr/gen/29564/ ...
... has added over,6,000 menu items from 70 of ... http://www.NutritionPedia.com, the only online nutrition,search engine. ... content of their favorite menu items available at ... style restaurants such as,Applebee,s Neighborhood Bar and Grill, ...
Cached Medicine News:Health News:MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions 2Health News:MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions 3Health News:Filtrona Fibertec Ningbo, China Plant Celebrates Expansion 2Health News:Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge 2Health News:Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge 3Health News:Video: GEN Video Hits Home with Web Audience 2Health News:NutritionPedia Adds Nutrition Facts for Over 6,000 Menu Items From 70 Leading Fast-Casual and Family Dining Restaurant Chains 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: